Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Open accessPublished version of a preprint
Abstract
Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC 50 s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Drug repositioning is a possible solution for combating the global coronavirus crisis.
“drug repositioning is a possible solution for combating the global coronavirus crisis [126].”
From Blockchain and AI-Based Solutions to Combat Coronavirus (COVID-19)-Like Epidemics: A Survey (2021) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575 · see citing works
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hú, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,967 · see citing works
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · see citing works
Beck, B. R., Shin, B., Choi, Y., Park, S., & Kang, K. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.025 · Cited by 815 · see citing works
Self-citationGassen, N. C., Niemeyer, D., Muth, D., Corman, V. M., Martinelli, S., Gassen, A., Hafner, K., Papies, J., Mösbauer, K., Zellner, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13659-4 · Cited by 356 · see citing works
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
Xu, J., Shi, P., Li, H., & Zhou, J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00052 · Cited by 334 · see citing works
Matsuyama, S., Kawase, M., Nao, N., Shirato, K., Ujike, M., Kamitani, W., Shimojima, M., & Fukushi, S. (2020) · Journal of Virology · doi:10.1128/jvi.01648-20 · Cited by 287 · see citing works
Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide
Wu, C., Jan, J., Chen, C.-M., Hsieh, H., Hwang, D.-R., Liu, H.-W., Liu, C.-Y., Huang, H.-W., Chen, S.-C., Hong, C.-F., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2693-2696.2004 · Cited by 240 · see citing works
The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15Preprint
Matsuyama, S., Kawase, M., Nao, N., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.11.987016 · Cited by 180 · see citing works
Beck, B. R., Shin, B., Choi, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.31.929547 · Cited by 139 · see citing works
More than 80 clinical trials launch to test coronavirus treatments
Maxmen, A. (2020) · Nature · doi:10.1038/d41586-020-00444-3 · Cited by 132 · see citing works
Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases
Iwabuchi, K., Yoshie, K., Kurakami, Y., et al. (2020) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2020.04.007 · Cited by 120 · see citing works
Absorption of pyrvinium pamoate
Smith, T. C., Kinkei, A. W., Gryczko, C. M., & Goulet, J. R. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976196802 · Cited by 62 · see citing works
Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma
Skoner, D. P., & Schaffner (2009) · Journal of Asthma and Allergy · doi:10.2147/jaa.s4651 · Cited by 19 · see citing works
Estimating the risk of 2019 Novel Coronavirus death during the course of the outbreak in China, 2020Preprint
Mizumoto, K., & Chowell, G. (2020) · medRxiv · doi:10.1101/2020.02.19.20025163 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Artificial intelligence in COVID-19 drug repurposing
Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30192-8 · Cited by 636 · see citing works
Si, L., Bai, H., Rodas, M., Cao, W., Oh, C. Y., Jiang, A., Moller, R., Hoagland, D., Oishi, K., Horiuchi, S., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00718-9 · Cited by 440 · see citing works
“This human Organ Chip model also successfully predicted the inability of chloroquine, hydroxychloroquine, and arbidol to work in animals 4 and human patients 1,2,55 , in contrast with what was reported in cell lines 42,56,57 .”
Self-citationBlockchain and AI-Based Solutions to Combat Coronavirus (COVID-19)-Like Epidemics: A Survey
Nguyen, D. C., Ding, M., Pathirana, P. N., & Seneviratne, A. (2021) · IEEE Access · doi:10.1109/access.2021.3093633 · Cited by 286 · see citing works
A critical overview of computational approaches employed for COVID-19 drug discovery
Muratov, E. N., Amaro, R., Andrade, C. H., Brown, N., Ekins, S., Fourches, D., Isayev, O., Kozakov, D., Medina-Franco, J. L., Merz, K. M., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01065k · Cited by 206 · see citing works
Zhou, Y., Hou, Y., Shen, J., Mehra, R., Kallianpur, A., Culver, D. A., Gack, M. U., Farha, S., Zein, J., Comhair, S., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000970 · Cited by 180 · see citing works
Almanza-Reyes, H., Moreno, S., Plascencia-López, I., Alvarado-Vera, M., Patrón-Romero, L., Borrego, B., Reyes-Escamilla, A., Valencia-Manzo, D., Brun, A., Pestryakov, A., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0256401 · Cited by 102 · see citing works
Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
Hosoki, K., Chakraborty, A., & Sur, S. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.033 · Cited by 63 · see citing works
- Authors
- Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., Shum, D., & Kim, S.
- Affiliations
- Institut Pasteur Korea (KR)
- Corresponding author
- Kim, Seungtaek
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2020-06-23
- Volume
- 64
- Issue
- 7
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC7318052
- OpenAlex
- W3023724901
- Cited by
- 675
- References
- 16
- Citations by year
- 2026: 18 · 2025: 23 · 2024: 47 · 2023: 80 · 2022: 128 · 2021: 193 · 2020: 186
- FWCI
- 19.39
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Research Foundation of Korea (NRF-2017M3A9G6068245, NRF-2020M3E9A1041756)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, antiviral drug candidates, drug repurposing, FDA-approved drugs, niclosamide, ciclesonide, SARS-CoV, inhibitory concentration, antiviral drug screening
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Animals, Anti-Inflammatory Agents, Antiviral Agents, Cell Line, Chlorocebus aethiops, Drug Evaluation, Preclinical, Humans, Niclosamide, Pneumonia, Viral, Pregnenediones, Vero Cells, Coronavirus Infections, Drug Repositioning, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
